Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,330 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: 2019 Novel Coronavirus Infection Clear all
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 11, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can COVID-19 Persist in Intraocular Fluid?

NCT04945850
View directory record Official record
Conditions
Ocular Infection, Viral
Interventions
routine care intraocular sx
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Back to ECE Safely With SAGE: Reducing COVID-19 Transmission in Hispanic and Low-income Preschoolers

NCT05178290
View directory record Official record
Conditions
COVID-19 Testing, Children, Preschool, Parents, Child Development, Self-Control, Exercise, Diet, Healthy
Interventions
CHILD back-to-ECE COVID-19 saliva testing, ECE personnel back-to-ECE COVID-19 saliva screening, SAGE garden programming
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
3 Years and older
Enrollment
1,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 11, 2026, 2:56 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 11, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Jun 11, 2026, 2:56 AM EDT
Terminated Phase 2 Interventional

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

NCT04339426
View directory record Official record
Conditions
Covid19
Interventions
Atovaquone/Azithromycin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 11, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
View directory record Official record
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

NCT04382924
View directory record Official record
Conditions
COVID
Interventions
NP-120 (Ifenprodil)
Drug
Lead sponsor
Algernon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Saint Joseph, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

NCT05947643
View directory record Official record
Conditions
COVID-19
Interventions
theophylline, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

NCT05566379
View directory record Official record
Conditions
Long COVID, Dysautonomia
Interventions
Mindfulness - Mindful Awareness Practices ( MAPs)
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jun 11, 2026, 2:56 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

NCT04858620
View directory record Official record
Conditions
Covid19
Interventions
Xlear Nasal Spray, Placebo
Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 11, 2026, 2:56 AM EDT
Not listed Phase 1Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia

NCT04527224
View directory record Official record
Conditions
Covid19 Pneumonia
Interventions
AstroStem-V
Drug
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jun 11, 2026, 2:56 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 11, 2026, 2:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)

NCT04513990
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 11, 2026, 2:56 AM EDT
Withdrawn No phase listed Observational

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874
View directory record Official record
Conditions
Coronavirus Disease, SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 11, 2026, 2:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19

NCT07405515
View directory record Official record
Conditions
POTS, POTS - Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Autonomic Dysfunction
Interventions
Blood Sample Collection
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 11, 2026, 2:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rutgers COVID-19 Cohort Study

NCT04336215
View directory record Official record
Conditions
Coronavirus, SARS-CoV-2
Interventions
Non-Interventional
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
20 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
7
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 11, 2026, 2:56 AM EDT
Completed No phase listed Observational

imPulse™ Una Full-spectrum, Over Clothing E-stethoscope

NCT04556149
View directory record Official record
Conditions
Corona Virus Infection, Coronavirus
Interventions
imPulse™ Una e-stethoscope, Philips Lumify Ultrasound System
Device
Lead sponsor
Level 42 AI, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jun 11, 2026, 2:56 AM EDT
No Longer Available No phase listed Expanded access

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

NCT05235347
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

NCT05975060
View directory record Official record
Conditions
COVID-19
Interventions
XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 54 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jun 11, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897
View directory record Official record
Conditions
COVID-19
Interventions
Brilacidin, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Winfield, Illinois • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Jun 11, 2026, 2:56 AM EDT